SS-31 gets talked about a lot in longevity circles. It is also one of the few "research peptides" that now has a real FDA-approved version. Here's how dosing and timing look in the trials versus how the community runs it. WHAT IT IS SS-31 is a small peptide that goes straight to your mitochondria, the parts of your cells that make energy. It sticks to a fat called cardiolipin on the inner membrane and helps keep that membrane stable. The drug name is elamipretide. WHERE IT'S APPROVED In September 2025 the FDA gave accelerated approval to elamipretide (brand name Forzinity) for Barth syndrome. That is a rare genetic mitochondria disease that weakens muscles and the heart. It was the first treatment ever approved for it. "Accelerated approval" means it was approved based on a muscle-strength measure, and the company still has to run a follow-up trial to confirm real-world benefit. HOW THE TRIALS AND LABEL DOSE IT • Injected under the skin once a day • Given at the same time each day • If a dose is missed, the label says skip it and do not double up • Label dose: 40 mg once a day for Barth syndrome patients who weigh at least 30 kg, with a lower dose for people with severe kidney problems That once-daily design is the main timing idea from the research. It was built for a serious rare disease, so it is not a template for healthy people. HOW IT'S COMMONLY RUN IN THE COMMUNITY Here's the standard schedule we reference in the community: • Vial: 10 mg • BAC water to reconstitute the whole vial: 2 ml • Dose: 500 mcg (10 units on a 1 ml syringe) • Timing: AM • Frequency: 5 days on, 2 days off • Cycle: 8 weeks on, 8 weeks off Stack lessons in the classroom can use a different schedule, so always follow the specific stack you're running. WHAT THE RESEARCH ACTUALLY SHOWS • Barth syndrome: small trials, with the muscle-strength signal that led to approval. Evidence level: Moderate. • A larger trial in adults with a different mitochondria muscle disease missed its main goals.

Sermorelin shows up a lot in growth-hormone talk, and two timing rules come with it almost every time: bedtime, and an empty stomach. Here's what those mean in plain English. WHAT IT IS Sermorelin is a short copy of the front end of GHRH, the signal your brain already sends to tell your pituitary to release growth hormone. It was sold as Geref and FDA-approved in 1997 for kids with growth-hormone deficiency. The brand was pulled from sale around 2008 for business reasons. In 2013 the FDA said that was not because of safety or effectiveness problems. Today it mainly shows up through compounding. GHRH VS GHRP, IN ONE LINE • GHRH-type (like Sermorelin): copies the brain's "release GH" signal. • GHRP-type (like Ipamorelin): uses a different receptor that also bumps GH release. People often stack one of each. That is a community pattern, not a required pair from a label. WHAT PEOPLE USE IT FOR • Supporting the body's own nighttime GH pulse • Sleep and recovery talk in adult wellness settings • A gentler entry point compared with taking growth hormone itself WHAT THE RESEARCH ACTUALLY SHOWS • The old pediatric trials used a once-daily bedtime injection. Evidence level for that labeled use in kids with GHD: Strong (historical approval + trials). • Adult anti-aging and wellness use is mostly clinic and community practice on top of that older pharmacology. Evidence level for adult wellness goals: Early to Anecdotal. • There is no current FDA-approved Sermorelin product on the market for adults. HOW IT'S COMMONLY RUN Here's the standard schedule we reference in the community: • Vial: 10 mg • BAC water to reconstitute the whole vial: 2 ml • Dose: 250 mcg (5 units on a 1 ml syringe) • Timing: PM (before bed) • Frequency: Monday–Friday • Cycle: 8 weeks on, 8 weeks off Stack lessons in the classroom can use a different schedule, so always follow the specific stack you're running. WHY BEDTIME COMES UP Your biggest natural GH pulse usually hits in the first stretch of deep sleep. The old Geref pediatric regimen was given at bedtime for that reason. Matching the shot to that window is the main timing idea in the research, not a forum invention.

⏱️ NAD+: HOW IV, INJECTION, NR, AND NMN DIFFER NAD+ comes up constantly, and it's sold in a bunch of different forms: IV drips, injections, and pills like NR and NMN. They aren't the same thing. Here's the simple breakdown. WHAT IT IS NAD+ is a helper molecule found in every cell in your body. Your cells need it to turn food into energy, and some of the enzymes that repair DNA depend on it too. Research suggests NAD+ levels drop in some tissues as we get older, which is why it gets so much attention for aging. WHAT PEOPLE USE IT FOR • Energy and fighting fatigue • Healthy-aging and longevity goals • Recovery and "brain fog" support THE DIFFERENT FORMS, IN PLAIN ENGLISH • NR (nicotinamide riboside) and NMN (nicotinamide mononucleotide): pills. These aren't NAD+ itself. They're building blocks, forms of vitamin B3, that your body turns into NAD+. • IV NAD+: NAD+ itself, dripped straight into a vein at a clinic. • Injected NAD+: NAD+ itself, injected under the skin with a small syringe. • Oral NAD+ pills: NAD+ is a big molecule, and when you swallow it, much of it gets broken down in the gut before it reaches your blood. That's why the pill research focuses on NR and NMN instead. WHAT THE RESEARCH ACTUALLY SHOWS • NR and NMN: Several small human trials show these pills reliably raise NAD+ levels in the blood. Whether that turns into real health benefits is less clear. A small 2021 trial of NMN in women with prediabetes found better muscle insulin sensitivity, but many other trials found few measurable changes. Evidence level: Moderate for raising NAD+, Early for actual benefits. • IV NAD+: Only small pilot studies. Clinics usually run drips slowly, often over a few hours, because faster drips are commonly linked to flushing, nausea, cramping, or chest tightness. Evidence level: Very Early. • Injected NAD+: Almost no published human research. Most of what's known comes from community experience. Evidence level: Anecdotal. No form of NAD+ is FDA-approved to treat aging or fatigue.

⏱️ MOTS-C: WHAT'S KNOWN ABOUT DOSING, TIMING, AND INJECTION-SITE REACTIONS MOTS-c gets talked about as an "exercise in a vial" peptide. The real story is more interesting, and a lot earlier-stage, than the hype. Here's the simple breakdown. WHAT IT IS MOTS-c is a small peptide (16 amino acids) that's coded in your mitochondria, the energy factories inside your cells. Scientists first described it in 2015. Your body makes it naturally, and levels go up when you exercise. WHAT PEOPLE USE IT FOR • Fat loss and metabolic support • Energy and exercise capacity • Healthy-aging and longevity goals WHAT THE RESEARCH ACTUALLY SHOWS • Animal studies: In mice, MOTS-c helped protect against weight gain and insulin resistance on a high-fat diet, and improved physical performance in older mice. Evidence level: Early (animal). • Human studies: Human research mostly measures the MOTS-c your body already makes, like how it rises with exercise. A drug company tested a modified version in early human trials, but that's not the same thing as the MOTS-c people inject. Controlled human trials of injected MOTS-c itself are basically missing. Evidence level: Very Early. HOW IT'S COMMONLY RUN Here's the standard schedule we reference in the community: • Vial: 10 mg • BAC water to reconstitute the whole vial: 2 ml • Dose: 1 mg (20 units on a 1 ml syringe) • Timing: AM • Frequency: 5 days on, 2 days off • Cycle: 8 weeks on, 8 weeks off Stack lessons in the classroom can use a different schedule for MOTS-c, so always follow the specific stack you're running. WHY AM TIMING COMES UP MOTS-c is tied to energy use and exercise in the research, so most people run it in the morning, often on training days. That's a community habit, not something a human trial has tested. INJECTION-SITE REACTIONS This is one of the most common things members bring up with MOTS-c: • Redness, a raised bump, itching, or stinging where it went in • Usually reported as short-lived • These are community reports, not trial data, so we don't know how common they really are

GHK-Cu is one of the most talked-about "skin and healing" peptides. It shows up in face serums and in injectable vials, and people mix up which research applies to which. Here's the simple breakdown. WHAT IT IS GHK-Cu is a tiny peptide (just three amino acids) bound to copper. Your body makes GHK naturally, and it's found in blood, saliva, and urine. The copper is why the liquid looks blue. WHAT PEOPLE USE IT FOR • Skin: firmness, fine lines, and overall skin quality • Healing: wound and tissue-repair support • Hair: scalp and hair-density goals (mostly lab data so far) TOPICAL VS INJECTED: THE BIG DIFFERENCE • Topical (creams and serums): This is where most of the human research lives. Small cosmetic studies on creams have reported improvements in skin firmness and fine lines. Many were small or industry-linked. Evidence level: Early to Moderate. • Injected (under the skin): This is how most of the community uses it, but there are basically no controlled human trials of injected GHK-Cu. The healing claims come mostly from cell and animal studies. Evidence level: Very Early. HOW IT'S COMMONLY RUN (INJECTABLE) Here's the standard schedule we reference in the community: • Vial: 50 mg • BAC water to reconstitute the whole vial: 3 ml • Dose: 1.7 mg (10 units on a 1 ml syringe) • Timing: AM • Frequency: Every day • Cycle: 8 weeks on, 8 weeks off Stack lessons in the classroom can use a different schedule for GHK-Cu, so always follow the specific stack you're running. COMMON QUESTIONS Why is it blue? That's the copper. A clear "GHK-Cu" is worth questioning. Does it sting? Injection-site stinging or redness is a common community report with GHK-Cu. That's anecdotal, not trial data. Can a serum do the same thing as an injection? They're different tools. Topical research is about skin on the surface. Injection claims are about whole-body healing, and those haven't been tested in people the same way. REALISTIC EXPECTATIONS Skin changes, when they happen, are slow and subtle, think weeks to months, not days. Treat big before-and-after claims with caution.